伊諾維奧製藥 INO 深 滬
等待開盤 12-18 09:30:00 美东时间
2.60
+0.280
+12.07%
華盛通- 最 高2.72
- 今 開2.31
- 成交量 455.48万股
- 最 低 2.30
- 昨 收 2.32
- 總市值 1.38亿
- 52周最高 2.9789
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 1.30
- 委 比 -25.03%
- 總股本 5314.27万
- 歷史最高 405.48
- 量 比 3.26
- 振 幅 18.10%
- 歷史最低 1.30
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%
Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%，与Coursera合并以扩大全球AI教育市场份额>>
今天 19:07
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $5 to $6.
11-15 00:06
Inovio Pharmaceuticals drops 6%, proposes equity offering
Inovio Pharmaceuticals (INO) proposed an underwritten public offering of its common stock, with all shares in the offering to be sold by the company itself. The underwriters have a 30-day option to pu...
11-11 14:33
Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses
Earnings Call Insights: Inovio Pharmaceuticals (INO) Q3 2025 Management View CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling sub...
11-11 08:32
INOVIO Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
NOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
11-11 07:14
Inovio Pharmaceuticals Q3 EPS $(0.87) Misses $(0.42) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.42) by 105.67 percent. This is a 2.25 percent increase over losses of $(0.89) per
11-11 05:03
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Nurix Therapeutics announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, with over two decades of leadership in drug development and commercialization, previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology. His expertise will strengthen Nurix’s efforts in advancing its lead asset, bexobrutideg, for chronic lymphocytic leukemia and exploring protein degradation in autoimmune ...
11-10 12:00
Inovio Pharmaceuticals Q3 2025 Earnings Preview
Inovio Pharmaceuticals (INO) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close. The consensus EPS Estimate is -$0.48 (+46.1% Y/Y)Over the last 2 years, INO has ...
11-10 06:35
